ly2066948 has been researched along with Uterine-Neoplasms* in 1 studies
1 other study(ies) available for ly2066948 and Uterine-Neoplasms
| Article | Year |
|---|---|
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. 16 (LY2066948-HCl) binds with high affinity to estrogen receptors alpha and beta (ERalpha and ERbeta, respectively) and is a potent uterine antagonist with minimal effects on the ovaries as determined by serum biomarkers and histologic evaluation. Topics: Animals; Binding Sites; Biological Availability; Cell Line; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Leiomyoma; Mammary Glands, Animal; Models, Molecular; Naphthalenes; Organ Size; Ovary; Piperidines; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Uterine Neoplasms; Uterus | 2005 |